NASDAQ: ZYBT
Zhengye Biotechnology Holding Ltd Stock

$4.35+0.14 (+3.33%)
Updated Feb 10, 2025
ZYBT Price
$4.35
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$3.70
52 Week High
$6.10
P/E
44.85x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$29.73M
Earnings
$5.29M
Gross Margin
61.4%
Operating Margin
22.77%
Profit Margin
14.9%
Debt to Equity
0.59
Operating Cash Flow
$7M
Beta
-1.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ZYBT's potential to beat the market

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ZYBT
Ranked
Unranked of 557

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ZYBT news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ZYBT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ZYBT was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ZYBT is poor value based on its earnings relative to its share price (44.85x), compared to the US market average (31x)
P/E vs Market Valuation
ZYBT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ZYBT due diligence checks available for Premium users.

Valuation

ZYBT price to earnings (PE)

For valuing profitable companies with steady earnings

Company
44.85x
Industry
-154.48x
Market
31x
ZYBT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ZYBT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

ZYBT's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ZYBT's Earnings (EBIT) of $6.77M... subscribe to Premium to read more.
Interest Coverage Financials
ZYBT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$70.5M
Liabilities
$22.7M
Debt to equity
0.59
ZYBT's short-term assets ($28.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZYBT's short-term assets ($28.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZYBT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
ZYBT's operating cash flow ($6.77M)... subscribe to Premium to read more.
Debt Coverage Financials

ZYBT vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ACETD$74.16M-6.74%-0.53x0.35x
ABCLD$892.01M-2.58%-4.95x0.83x
AAPGN/A+1.23%N/AN/A
ABUSC$631.01M-2.92%-7.74x5.90x
ABSID$497.33M-7.28%-4.66x2.47x

Zhengye Biotechnology Holding Stock FAQ

What is Zhengye Biotechnology Holding's quote symbol?

(NASDAQ: ZYBT) Zhengye Biotechnology Holding trades on the NASDAQ under the ticker symbol ZYBT. Zhengye Biotechnology Holding stock quotes can also be displayed as NASDAQ: ZYBT.

If you're new to stock investing, here's how to buy Zhengye Biotechnology Holding stock.

What is the 52 week high and low for Zhengye Biotechnology Holding (NASDAQ: ZYBT)?

(NASDAQ: ZYBT) Zhengye Biotechnology Holding's 52-week high was $6.10, and its 52-week low was $3.70. It is currently -28.69% from its 52-week high and 17.57% from its 52-week low.

How much is Zhengye Biotechnology Holding's stock price per share?

(NASDAQ: ZYBT) Zhengye Biotechnology Holding stock price per share is $4.35 today (as of Feb 10, 2025).
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.